Mural Oncology (NASDAQ:MURA) Rating Lowered to Outperform at Raymond James
Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating to an “outperform” rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have a $18.00 target price on the stock. Other equities research analysts also recently issued research reports about the stock. HC […]
Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating to an “outperform” rating in a report issued on Tuesday, Marketbeat Ratings reports. They currently have a $18.00 target price on the stock. Other equities research analysts also recently issued research reports about the stock. HC […]
